Enalapril of the tab. of 10 mg No. 20

Enalapril is an inhibitor of angiotensin-converting enzyme, monocomponent, for treatment of arterial hypertension, treatment of clinically apparent heart failure, prevention of clinically apparent heart failure at patients with asymptomatic dysfunction of a left ventricle (fraction of emission ≤ 35%).

Structure

• 1 tablet contains maleate enalapril (in terms of 100% substance) - 10 mg;
• excipients: lactose monohydrate, potato starch; cellulose microcrystalline povidone, silicon dioxide colloidal talc of calcium stearate.

Contraindication

Hypersensitivity to enalapril, to any excipient or to the APF any other inhibitor.

Existence in the anamnesis of the Quincke's disease connected with use of APF inhibitors.

Hereditary or idiopathic Quincke's disease.

Arterial hypertension

Dose of medicament makes

from initial 5 mg to the maximum 20 mg depending on degree of arterial hypertension and a condition of the patient. To accept enalapril 1 time a day. In arterial hypertension of easy degree the recommended initial dose makes 5-10 mg.

Heart failure / asymptomatic dysfunction of a left ventricle

enalapril is applied by

To treatment of clinically apparent heart failure with diuretics and, in case of need, medicaments of a foxglove or β-blockers. The initial dose of Enalapril for patients with clinically apparent heart failure or asymptomatic dysfunction of a left ventricle makes 2.5 mg, at the same time use of medicament needs to be carried out under careful medical control to establish primary influence of medicament on arterial blood pressure.

Feature of use

At some patients with heart failure with the normal or lowered pressure, enalapril can reduce the level of arterial blood pressure in addition. Such reaction to administration of medicament is expected and usually is not the basis for the treatment termination. In case arterial hypotension becomes resistant to treatment, it is necessary to reduce a dose and/or to stop treatment by diuretic and/or Enalapril.

Pregnant

pregnant women or women planning pregnancy should not use Drug.

to Apply

to children aged from 6 years.

Drivers

At control of motor transport or work with other mechanisms should consider possible development of dizziness or increased fatigue.

Overdose

Main signs of overdose, according to the available data, is the profound arterial hypotension which begins approximately in 6 hours after administration of medicament and matches blockade renin-angiotensin, and a stupor. The symptoms connected with overdose by APF inhibitors can include circulator shock, an electrolytic imbalance, a renal failure, a hyperventilation of lungs, tachycardia, a cardiopalmus, bradycardia, dizziness, uneasiness and cough.

Side effects

from blood: anemia (including aplastic and hemolytic), a neutropenia, decrease in hemoglobin, decrease in a hematocrit, thrombocytopenia, an agranulocytosis, oppression of marrow, a pancytopenia, a lymphadenopathy, autoimmune diseases, a leukopenia.

from an endocrine system: syndrome of disturbance of secretion of ADG.

Metabolic disturbances: hypoglycemia.

from nervous system and mentality: depression, headache, confusion of consciousness, drowsiness, insomnia, nervousness, paresthesia, vertigo, sleep disorders, abnormal dreams, dizziness.

from an organ of sight: illegibility of sight, disorder of vision.

to Store

in original packing at a temperature not above 25 °C.

to Store

out of children's reach.